Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2− Metastatic Breast Cancer

被引：0
|
作者：
Annie Guérin
Debbie Goldschmidt
Tania Small
Patrick Gagnon-Sanschagrin
Hela Romdhani
Genevieve Gauthier
Sneha Kelkar
Eric Q. Wu
Polly Niravath
Anand A. Dalal
机构：
[1] Analysis Group,
[2] Inc.,undefined
[3] Analysis Group,undefined
[4] Inc.,undefined
[5] Novartis Pharmaceuticals Corporation,undefined
[6] Analysis Group,undefined
[7] Inc.,undefined
[8] Houston Methodist Hospital,undefined
来源：
Advances in Therapy | 2018年 / 35卷
关键词：
CDK4/6 inhibitor; HR+/HER2−; Metastatic breast cancer; Monitoring; Oncology; Post-menopausal;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1251 / 1264
页数：13
相关论文
共 50 条
  • [21] Observational study of HR+/HER2− metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS)
    Salvador Blanch
    Juan Miguel Gil-Gil
    Miriam Arumí
    Elena Aguirre
    Miguel Ángel Seguí
    Manuel Atienza
    Silvia Díaz-Cerezo
    Alberto Molero
    José Manuel Cervera
    Joaquín Gavilá
    Clinical and Translational Oncology, 2023, 25 : 2950 - 2959
  • [22] Physician experiences and preferences in the treatment of HR+/HER2-metastatic breast cancer in the United States: aphysician survey
    Lin, Peggy L.
    Hao, Yanni
    Xie, Jipan
    Li, Nanxin
    Zhong, Yichen
    Zhou, Zhou
    Signorovitch, James E.
    Wu, Eric Q.
    CANCER MEDICINE, 2016, 5 (02): : 209 - 220
  • [23] The prognostic impact of BMI in patients with HR+/HER2− advanced breast cancer: a study of the SONABRE registry
    Senna W. M. Lammers
    Hannah Thurisch
    Ingeborg J. H. Vriens
    Marissa Meegdes
    Sanne M. E. Engelen
    Frans L. G. Erdkamp
    M. Wouter Dercksen
    Birgit E. P. J. Vriens
    Kirsten N. A. Aaldering
    Manon J. A. E. Pepels
    Linda M. H. van de Winkel
    Natascha A. J. B. Peters
    Jolien Tol
    Joan B. Heijns
    Agnes J. van de Wouw
    Nathalie J. A. Teeuwen
    Sandra M. E. Geurts
    Vivianne C. G. Tjan-Heijnen
    Breast Cancer Research and Treatment, 2024, 203 : 339 - 349
  • [24] Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice
    Sini, Valentina
    Cinieri, Saverio
    Conte, Pierfranco
    De Laurentiis, Michelino
    Di Leo, Angelo
    Tondini, Carlo
    Marchetti, Paolo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 100 : 57 - 68
  • [25] Survey of Health Care Providers on Social Determinants of Health and Treatment Decision-Making for Patients With HR+/HER2− Metastatic Breast Cancer
    Monique Gary
    Editha Krueger
    Molly Kisiel
    Kimberly Demirhan
    Alexandra Guarin Barajas
    Joanne C. Ryan
    Oncology and Therapy, 2025, 13 (2) : 429 - 446
  • [26] The effects of HER2 monoclonal antibody in women with HER2-overexpressing metastatic breast cancer
    Boer R.
    Breast Cancer Research, 1 (1)
  • [27] Patterns and outcomes in HR+/HER2-advanced/metastatic breast cancer patients in Brazil receiving palbociclib
    Simon, Patricia
    Jain, Ankita
    Guarin, Alexandra
    Piton, Luciana
    Carvalho, Carla Fabrine
    Lima, Julia
    Nazareth, Felipe
    FUTURE ONCOLOGY, 2024, : 2647 - 2659
  • [28] Controversial topics in metastatic HR+/HER2-breast cancer: Guiding treatment by a modified Delphi approach
    Fabi, Alessandra
    Buono, Giuseppe
    Bria, Emilio
    Bianchini, Giampaolo
    Curigliano, Giuseppe
    De Laurentiis, Michelino
    De Placido, Sabino
    Del Mastro, Lucia
    Guarneri, Valentina
    Generali, Daniele
    Livi, Lorenzo
    Lorusso, Vito
    Montemurro, Filippo
    Puglisi, Fabio
    Vigneri, Paolo
    Zambelli, Alberto
    Arpino, Grazia
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [29] Real-world effectiveness of palbociclib in HR+/HER2- metastatic breast cancer: a literature review
    Christiansen, Emilie Adrian
    Kuemler, Iben
    FUTURE SCIENCE OA, 2024, 10 (01):
  • [30] Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2– metastatic breast cancer in the United States
    Ravi K. Goyal
    Holly M. Holmes
    Hua Chen
    Susan Abughosh
    Sean D. Candrilli
    Michael L. Johnson
    Breast Cancer Research and Treatment, 2023, 198 : 159 - 166
12345